These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 32617699)
1. Ruxolitinib combined with doxorubicin, etoposide, and dexamethasone for the treatment of the lymphoma-associated hemophagocytic syndrome. Zhou L; Liu Y; Wen Z; Yang S; Li M; Zhu Q; Qiu S; Gao Y; Wang H; Yuan Y; Zhang H; Chen C; Zeng W; Guan Z; Pan X J Cancer Res Clin Oncol; 2020 Nov; 146(11):3063-3074. PubMed ID: 32617699 [TBL] [Abstract][Full Text] [Related]
2. The emerging role of anti-PD-1 antibody-based regimens in the treatment of extranodal NK/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis. He Y; Gao Y; Ping L; He H; Huang C; Bai B; Wang X; Li Z; Cai Q; Huang Y; Pan X; Zeng W; Liu Y; Huang H J Cancer Res Clin Oncol; 2023 May; 149(5):2017-2027. PubMed ID: 35809114 [TBL] [Abstract][Full Text] [Related]
3. Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis. Wei L; Yang L; Cong J; Ye J; Li X; Yao N; Yang J; Ding J; Wang J J Cancer Res Clin Oncol; 2021 Mar; 147(3):863-869. PubMed ID: 33025280 [TBL] [Abstract][Full Text] [Related]
4. Lymphoma-associated hemophagocytic syndrome: a retrospective, single-center study of 86 patients. Cheng S; Yan Z; Ma H; Liu Y Ann Hematol; 2024 Sep; 103(9):3649-3656. PubMed ID: 39078433 [TBL] [Abstract][Full Text] [Related]
5. [Clinical characteristics and prognosis of lymphoma-associated hemophagocytic syndrome]. Zhao AL; Li M; Li LF; Gan XA; Wang J; Li H; Shen K; Yang YF; Niu T Zhonghua Yi Xue Za Zhi; 2022 Jul; 102(28):2173-2180. PubMed ID: 35872581 [No Abstract] [Full Text] [Related]
6. The significance of pre-therapeutic F-18-FDG PET-CT in lymphoma-associated hemophagocytic lymphohistiocytosis when pathological evidence is unavailable. Wang J; Wang D; Zhang Q; Duan L; Tian T; Zhang X; Li J; Qiu H J Cancer Res Clin Oncol; 2016 Apr; 142(4):859-71. PubMed ID: 26666755 [TBL] [Abstract][Full Text] [Related]
7. Ruxolitinib-combined doxorubicin-etoposide-methylprednisolone regimen as a salvage therapy for refractory/relapsed haemophagocytic lymphohistiocytosis: a single-arm, multicentre, phase 2 trial. Wang J; Zhang R; Wu X; Li F; Yang H; Liu L; Guo H; Zhang X; Mai H; Li H; Wang Z Br J Haematol; 2021 May; 193(4):761-768. PubMed ID: 33559893 [TBL] [Abstract][Full Text] [Related]
8. Identification of clinical features of lymphoma-associated hemophagocytic syndrome (LAHS): an analysis of 69 patients with hemophagocytic syndrome from a single-center in central region of China. Li F; Li P; Zhang R; Yang G; Ji D; Huang X; Xu Q; Wei Y; Rao J; Huang R; Chen G Med Oncol; 2014 Apr; 31(4):902. PubMed ID: 24610542 [TBL] [Abstract][Full Text] [Related]
9. High concentration of miR-133 is a useful marker for the diagnosis of lymphoma- associated hemophagocytic syndrome. Li W; Zhong Y; Shuang Y; Huang H; Huang Y; Yu L; Huang X Cancer Biomark; 2017 Aug; 20(2):159-164. PubMed ID: 28869447 [TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr Virus-Positive Lymphoma-Associated Hemophagocytic Syndrome: A Retrospective, Single-Center Study of 51 Patients. Zhao A; Yang J; Li M; Li L; Gan X; Wang J; Li H; Shen K; Yang Y; Niu T Front Immunol; 2022; 13():882589. PubMed ID: 35479073 [TBL] [Abstract][Full Text] [Related]
11. Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: A case series. Hansen S; Alduaij W; Biggs CM; Belga S; Luecke K; Merkeley H; Chen LYC Eur J Haematol; 2021 May; 106(5):654-661. PubMed ID: 33523540 [TBL] [Abstract][Full Text] [Related]
12. Clinical features and treatment of natural killer/T cell lymphoma associated with hemophagocytic syndrome: comparison with other T cell lymphoma associated with hemophagocytic syndrome. Han L; Li L; Wu J; Li X; Zhang L; Wang X; Fu X; Ma W; Sun Z; Zhang X; Chang Y; Guo S; Zhang M Leuk Lymphoma; 2014 Sep; 55(9):2048-55. PubMed ID: 24359240 [TBL] [Abstract][Full Text] [Related]
13. Requirement for containing etoposide in the initial treatment of lymphoma associated hemophagocytic lymphohistiocytosis. Song Y; Wang J; Wang Y; Wu L; Wang Z Cancer Biol Ther; 2021 Dec; 22(10-12):598-606. PubMed ID: 34724875 [TBL] [Abstract][Full Text] [Related]
14. Ruxolitinib for hematopoietic cell transplantation-associated hemophagocytic lymphohistiocytosis. Ono R; Ashiarai M; Hirabayashi S; Mizuki K; Hosoya Y; Yoshihara H; Ohtake J; Mori S; Manabe A; Hasegawa D Int J Hematol; 2021 Feb; 113(2):297-301. PubMed ID: 32979171 [TBL] [Abstract][Full Text] [Related]
15. Autologous Hematopoietic Stem Cell Transplantation for Patients with Lymphoma-Associated Hemophagocytic lymphohistiocytosis. Song Y; Yin Q; Wang J; Wang Z Cell Transplant; 2021; 30():9636897211057077. PubMed ID: 34743574 [TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics of T-cell lymphoma associated with hemophagocytic syndrome: comparison of T-cell lymphoma with and without hemophagocytic syndrome. Tong H; Ren Y; Liu H; Xiao F; Mai W; Meng H; Qian W; Huang J; Mao L; Tong Y; Wang L; Qian J; Jin J Leuk Lymphoma; 2008 Jan; 49(1):81-7. PubMed ID: 18203016 [TBL] [Abstract][Full Text] [Related]
17. Ruxolitinib in conjunction with the HLH-94 protocol for Epstein-Barr virus-related hemophagocytic lymphohistiocytosis in the intensive care unit: A case report. Huang Z; Xie J Medicine (Baltimore); 2021 Mar; 100(11):e25188. PubMed ID: 33726009 [TBL] [Abstract][Full Text] [Related]
18. Ruxolitinib for the treatment of lymphoma-associated hemophagocytic lymphohistiocytosis: A cautionary tale. Trantham T; Auten J; Muluneh B; Van Deventer H J Oncol Pharm Pract; 2020 Jun; 26(4):1005-1008. PubMed ID: 31575356 [TBL] [Abstract][Full Text] [Related]
19. Elevated Interleukin-10 Levels Are Associated with Low Platelet Count and Poor Prognosis in 90 Adult Patients with Hemophagocytic Lymphohistiocytosis. Hao L; Ren J; Zhu Y; Ma Y; Pan J; Yang L Int Arch Allergy Immunol; 2023; 184(4):400-408. PubMed ID: 36634629 [TBL] [Abstract][Full Text] [Related]
20. Ruxolitinib is an alternative to etoposide for patient with hemophagocytic lymphohistiocytosis complicated by acute renal injury: A case report. Yan WL; Yang SL; Zhao FY; Xu XJ J Oncol Pharm Pract; 2022 Jan; 28(1):222-227. PubMed ID: 34074166 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]